Can I read 45724 VC2 Oncolytic Virotherapy Induces Robust Systemic Anti-Tumor Immunity and Increases Survival in an Immunocompetent B16F10-derived Mouse Melanoma Model on EtoBox?

45724 VC2 Oncolytic Virotherapy Induces Robust Systemic Anti-Tumor Immunity and Increases Survival in an Immunocompetent B16F10-derived Mouse Melanoma Model by Uche, Ifeanyi Kingsley (author);Fowlkes, Natalie (author);Vu, Luan (author);Watanabe, Tatiane (author);Carossino, Mariano (author);Nabi, Rafiq (author);Del Piero, Fabio (author);Rudd, Jared S. (author);Kousoulas, Konstantin G. (author);Rider, Paul J.F. (author) is a Medicine article available to read on EtoBox.

What is 45724 VC2 Oncolytic Virotherapy Induces Robust Systemic Anti-Tumor Immunity and Increases Survival in an Immunocompetent B16F10-derived Mouse Melanoma Model about?

ABSTRACT IMPACT: Our data demonstrate that VC2 oncolytic virotherapy has significant clinical potential. OBJECTIVES/GOALS: Use our novel oncolytic herpes simplex virus type I (HSV-1), VC2, to understand how oncolytic virotherapy affects the immunosuppressive tumor microenvironment as a mechanism of efficacy. METHODS/STUDY POPULATION: We tested the efficacy of VC2 as an oncolytic virotherapy (OVT) in a syngeneic B16F10-derived mouse model of melanoma. We modified the B16F10 to express nectin-1 (B16F10n-1), the major receptor for HSV-1. Engrafted B16F10n-1 tumors were intratumorally treated with either phosphate-buffered saline (PBS) or 1x10^6 pfu VC2. At indicated time points, treated tumors were excised and processed for immunohistochemistry or flow cytometry analysis. For our experimental metastasis studies, mice were intravenously challenged with B16F10n-1 cells. For our depletion studies, CD4+ and CD8+ T cells were depleted in mice by treatment with mouse anti-CD4 and anti-CD8 monoclonal antibodies respectively, while the control mice were given Rat IgG2b isotype. RESULTS/ANTICIPATED RESULTS: We found that VC2 slowed tumor growth rates and significantly enhanced survival times o

Who reads 45724 VC2 Oncolytic Virotherapy Induces Robust Systemic Anti-Tumor Immunity and Increases Survival in an Immunocompetent B16F10-derived Mouse Melanoma Model?

Author

Uche, Ifeanyi Kingsley (author);Fowlkes, Natalie (author);Vu, Luan (author);Watanabe, Tatiane (author);Carossino, Mariano (author);Nabi, Rafiq (author);Del Piero, Fabio (author);Rudd, Jared S. (author);Kousoulas, Konstantin G. (author);Rider, Paul J.F. (author)

Publisher

Cambridge University Press (CUP)

Published

2021

Language

EN

Field

Medicine (Health Sciences)